P456: Ig glycosylation in ulcerative colitis: it's time for new biomarkersECCO'21 VirtualYear: 2021
Authors: Capecchi, R.(1);Migliorini, P.(1);Zanzi, F.(1);Maltinti, S.(1);Puxeddu, I.(1);De Bortoli, N.(1);Bellini, M.(1);Costa, F.(2);Marchi, S.(1);Bertani, L.(1);
(1)University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy;(2)Pisa University Hospital, General Surgery and Gastroenterology - IBD Unit, Pisa, Italy
P458: Effectiveness of biological therapy for pouchitis and other inflammatory complications ot the pouch. And the question of a second Anti-TNF after failure? Results from the RESERVO Study of GETECCU.ECCO'21 VirtualYear: 2021
Authors: Mesonero Gismero, F.(1);Zabana, Y.(2);Fernández-Clotet, A.(3);Núñez, A.(4);Caballol, B.(3);Sola, A.(4);García, M.J.(5);Bertoletti, F.(6);Mínguez, A.(7);Suris, G.(8);Casis, B.(9);Ferreiro-Iglesias, R.(10);Calafat, M.(11);Jiménez, I.(12);Miranda-Bautista, J.(13);Lamuela, L.J.(14);Fajardo, I.(15);Torrealba, L.(16);Nájera, R.(17);Sáiz, R.M.(18);González, I.(19);Vicuña, M.(20);García-Morales, N.(21);Gutiérrez, A.(22);López-García, A.(23);Benítez, J.M.(24);Rubín de Célix, C.(25);Tejido, C.(26);Brunet, E.(27);Hernández, A.(28);Suárez, C.(29);Piquqeras, M.(30);Castaño, A.(31);Ramos, L.(32);Sobrino, A.(33);Rodríguez-Grau, M.C.(34);Elosua, A.(35);Montoro, M.(36);López-Sanromán, A.(1);Barreiro-de Acosta, M.(10);
(1)Hospital Universitario Ramón y Cajal, Department of Gastroenterology, Madrid, Spain;(2)Hospital Universitari Mútua Terrassa. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd., Gastroenterology, Barcelona, Spain;(3)Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Universitario Virgen del Rocío, Gastroenterology, Sevilla, Spain;(5)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology, Santander, Spain;(6)Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(7)Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain;(8)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(9)Hospital Universitario 12 de Octubre, Gastroenterology, Madrid, Spain;(10)Hospital Clínico Universitario Santiago, Gastroenterology, Santiago de Compostela, Spain;(11)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(12)Hospital Universitario Galdakao, Gastroenterology, Bilbao, Spain;(13)Hospital Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain;(14)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(15)Hospital Universitari Mútua Terrassa, Gastroenterology, Barcelona, Spain;(16)Hospital Universitari Doctor Josep Trueta, Gastroenterology, Girona, Spain;(17)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(18)Hospital Universitario Burgos, Gastroenterology, Burgos, Spain;(19)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain;(20)Complejo Hospitalario Navarra, Gastroenterology, Pamplona, Spain;(21)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(22)Hospital General Universitario Alicante. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd. Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL., Gastroenterology, Alicante, Spain;(23)Hospital del Mar, Gastroenterology, Barcelona, Spain;(24)Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain;(25)Hospital Universitario La Princesa. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd. Instituto de Investigación Sanitaria Princesa IIS-IP., Gastroenterology, Madrid, Spain;(26)Complejo Hospitalario Universitario Ourense, Gastroenterology, Ourense, Spain;(27)Hospital Universitari Parc Taulí, Gastroenterology, Sabadell, Spain;(28)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Tenerife, Spain;(29)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(30)Consorci Sanitari Terrassa, Gastroenterology, Barcelona, Spain;(31)Hospital Universitario Central Asturias, Gastroenterology, Oviedo, Spain;(32)Hospital Universitario de Canarias, Gastroenterology, Tenerife, Spain;(33)Hospital General Universitario Ciudad Real, Gastroenterology, Ciudad Real, Spain;(34)Hospital Universitario del Henares, Gastroenterology, Coslada, Spain;(35)Hospital García Orcoyen, Gastroenterology, Estella, Spain;(36)Hospital General Universitario San Jorge, Gastroenterology, Huesca, Spain; On behalf of the Young Group of GETECCU. RESERVO Study Group: Baston I Rodríguez Lago I Baltar R Huguet JM Hermida B Caballero-Mateos A Sánchez-Guillén L Bouhmidi A Pajares R.
P459: Change in the expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Jójárt, B.(1);Molnár, T.(2);Szabó, V.(1);Varga, Á.(1);Resál, T.(3);Szántó, K.(3);Kata, D.(4);Földesi, I.(4);Molnár, T.(3);Maléth, J.(5);Farkas, K.(3);
(1)University of Szeged, Faculty of Medicine- First Department of Medicine- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group- HCEMM-USz Molecular Gastroenterology Research Group, Szeged, Hungary;(2)University of Szeged, Faculty of Medicine- First Department of Medicine- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group, Szeged, Hungary;(3)University of Szeged, Faculty of Medicine- First Department of Medicine, Szeged, Hungary;(4)University of Szeged, Faculty of Medicine - Institute of Laboratory Medicine, Szeged, Hungary;(5)University of Szeged, Faculty of Medicine- First Department of Medicine- Department of Public Health- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group- HCEMM-USz Molecular Gastroenterology Research Group, Szeged, Hungary; Hungarian Academy of Science - University of Szeged Momentum Epithelial Cell Signaling and Secretion Research Group
P460: Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn’s disease undergoing infliximab induction therapyECCO'21 VirtualYear: 2021
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);Weersma, R.K.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
(1)Nordic Bioscience, Immunoscience, Herlev, Denmark;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands
P462: Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center studyECCO'21 VirtualYear: 2021
Authors: de Seze, M.(1);Billiauws, L.(1);Bettolo, J.(1);Damas, V.(1);Hutinet, C.(1);Bonvalet, F.(2);Cazals-Hatem, D.(3);Villain, C.(1);Bouhnik, Y.(1);Joly, F.(1);Uzzan, M.(4);
(1)Hopital Beaujon, Gastroenterology, Clichy, France;(2)Hopital Beaujon, Radiology, Clichy, France;(3)Hopital Beaujon, Pathology, Clichy, France;(4)Hôpital Beaujon- APHP, Gastroenterology- IBD unit, Paris, France
P463: COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI Onlus).ECCO'21 VirtualYear: 2021
Authors: Costantino, A.(1);Noviello, D.(2);Conforti, F.S.(1);Aloi, M.(3);Armuzzi, A.(4);Bossa, F.(5);Ficari, F.(6);Leone, S.(7);Manguso, F.(8);Mocci, G.(9);Orlando, A.(10);Pironi, L.(11);Radice, S.(12);Rizzello, F.(13);Tongiorgi, A.(14);Costantino, C.(15);Vecchi, M.(1,2);Caprioli, F.(1,2);
(1)IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Gastroenterology and Endoscopy Unit, Milan, Italy;(2)University of Milan, Department of Pathophysiology and Transplantation, Milano, Italy;(3)Sapienza University of Rome, Department of Pediatrics, Rome, Italy;(4)Fondazione Policlinico Universitario A. Gemelli IRCCS, Internal Medicine and Gastroenterology, Rome, Italy;(5)Fondazione casa sollievo della sofferenza, Gastroenterologia ed Endoscopia Digestiva, San Giovanni Rotondo, Italy;(6)AUO Careggi, Dipartimento di Medicina Sperimentale Clinica Chirurgia Generale, Florence, Italy;(7)AMICI onlus, AMICI onlus, Milan, Italy;(8)AO Cardarelli, Surgical Department, Napoli, Italy;(9)Azienda Ospedaliera ARNAS G. Brotzu, SC Gastroenterologia, Cagliari, Italy;(10)“Villa Sofia-Cervello” Hospital, IBD Unit, Palermo, Italy;(11)Policlinico Sant'Orsola Malpighi Centro IICB, Scienze Mediche, Bologna, Italy;(12)Humanitas Research Hospital, IBD Unit, Milan, Italy;(13)Policlinico Sant'Orsola Malpighi, Department of Internal Medicine and Gastroenterology, Bologna, Italy;(14)UO Gastroenterologia AOUP, Chirurgia Generale, Pisa, Italy;(15)Department of Health Promotion Sciences- Maternal and Infant Care- Internal Medicine and Excellence Specialties 'G. D'Alessandro', University of Palermo, Palermo, Italy
P464: Steroid dependency in patients with Ulcerative Colitis treated with advanced therapies in a German real-world-settingECCO'21 VirtualYear: 2021
Authors: Bokemeyer, B.(1);Picker, N.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
(1)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(2)Ingress Health, HWM GmbH, Wismar, Germany;(3)IPAM, e.V., Wismar, Germany;(4)Galapagos, Biopharma Deutschland GmbH, München, Germany;(5)Galapagos, Nv, Mechelen, Belgium
P465: One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitisECCO'21 VirtualYear: 2021
Authors: Verstockt., B.(1,2);Aden, K.(3,4);Alsoud, D.(2);Outtier, A.(1);Sabino, J.(1,2);Rosenstiel, P.(3,4);Vermeire, S.(1,2);De Hertogh, G.(5);Schreiber, S.(3,4);Ferrante, M.(1,2);
(1)University Hospitals Leuven, Dpt. Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Dpt. Chronic Diseases- Metabolism and Ageing- TARGID-IBD, Leuven, Belgium;(3)Christian-Albrechts-University and University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany;(4)Christian-Albrechts-University and University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(5)University Hospitals Leuven, Laboratory of Morphology and Molecular Pathology, Leuven, Belgium
P466: Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab.ECCO'21 VirtualYear: 2021
Authors: Fasoulas, K.(1);Soufleris, K.(1);Kafalis, N.(1);Kevrekidou, P.(1);Bouzoukas, S.(1);Stergiou, E.(1);Dimitriadis, N.(1);Chatzopoulos, E.(1);Tzilves, D.(1);
(1)Theageneio Anticancer Hospital, Gastroenterology, Thessaloniki, Greece
P467: Perception Gap between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional StudyECCO'21 VirtualYear: 2021
Authors: Liang , J.(1);Cao , Q.(2);Chen , M.(3);Wu , K.(1);
(1)Xijing Hospital, Department of Gastroenterology, Xi An, China;(2)Zhejiang University School Of Medicine Sir Run Run Shaw Hospital, Department of Gastroenterology, Hangzhou, China;(3)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China
P468: Analysis of international spontaneous reporting system databases for safety of corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and consequences of Corticosteroid Excess (DICE)-impact studyECCO'21 VirtualYear: 2021
Authors: Raine, T.(1);Bokemeyer, B.(2);Finney-Hayward, T.(3);Munsaka, M.(4);Liu, M.(4);Louis, E.(5);
(1)Addenbrooke’s Hospital University of Cambridge, Gastroenterology, Cambridge, United Kingdom;(2)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(3)AbbVie Ltd, Gastroenterology, Maidenhead, United Kingdom;(4)AbbVie Inc., Safety Statistics, North Chicago IL, United States;(5)CHU Liège University Hospital, Gastroenterology, Liège, Belgium
P469: The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s diseaseECCO'21 VirtualYear: 2021
Authors: Dignass, A.(1);Gisbert, J.(2);Freudensprung, U.(3);Addison, J.(4);
(1)Agaplesion Markus Hospital- Goethe University, Department of Medicine 1, Frankfurt, Germany;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Universidad Autónoma de Madrid, Gastroenterology Unit, Madrid, Spain;(3)Biogen International GmbH, None, Baar, Switzerland;(4)Biogen Idec, None, Maidenhead, United Kingdom
P470: Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease PatientsECCO'21 VirtualYear: 2021
Authors: Zelinkova, Z.(1);Lipovska, A.(2);Otottova, K.(2);Lucenicova, J.(3);Kadleckova, B.(2);
(1)St. Michael`s Hospital, Gastroenterology&Digestive Endoscopy, Bratislava, Slovakia;(2)St. Michael`s Hospital, Department of Gastroenterology&Digestive Endoscopy, Bratislava, Slovakia;(3)St. Michael`s Hospital, Department Clinical Biochemistry&Hematology, Bratislava, Slovakia
P471: Predictors of bowel damage in long term progression of Crohn’s diseaseECCO'21 VirtualYear: 2021
Authors: Fernandez Clotet, A.(1);Panes, J.(1);Ricart, E.(1);Castro Poceiro, J.(1);Masamunt, M.C.(1);Rodríguez, S.(2);Caballol, B.(1);Ordas, I.(1);Rimola, J.(2);
(1)Hospital Clinic de Barcelona, Gastroenterology department, Barcelona, Spain;(2)Hospital Clinic de Barcelona, Radiology department, Barcelona, Spain
P472: Payer addressable burden of Crohn’s disease in patients treated with ustekinumab and vedolizumab in the United StatesECCO'21 VirtualYear: 2021
Authors: Ghosh, T.(1);Smith, I.(2);Fehr, J.(2);Davidson, J.(2);Fan, T.(3);Candela, N.(4);Tsang, C.(5);Koch, T.(5);
(1)Takeda Pharmaceuticals USA Inc., US Medical Outcomes Research, Lexington, United States;(2)OptumInsight, Pharmacy Advisory Services, Eden Prairie, United States;(3)Takeda Pharmaceuticals USA Inc., US Medical Economics and Outcomes Research, Lexington, United States;(4)Takeda Pharmaceuticals USA Inc., US Medical GI, Lexington, United States;(5)Takeda Pharmaceuticals USA Inc., US Medical, Lexington, United States
P473: Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Amiama Roig, C.(1);Suárez Ferrer, C.(1);Poza Cordón, J.(1);Rueda García, J.L.(1);Sánchez Azofra, M.(1);Martín Arranz, E.(1);González Díaz, I.(1);Amor Costa, C.(1);García Ramírez, L.(2);Martín Arranz, M.D.(1);
(1)La Paz University Hospital, Department of Gastroenterology and Hepatology, Madrid, Spain;(2)La Paz University Hospital, Hospital La Paz Institute for Health Research- IdiPAZ, Madrid, Spain
